Leman Biotech

Leman Biotech

Biotechnologieforschung

Lausanne, Vaud 1.996 Follower:innen

Leman Biotech, a spin-off company of EPFL, aims at developing and commercializing new metabolic cancer immunotherapies

Info

Leman Biotech Co., Ltd. is a spin-off of EPFL co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering). Leman Biotech aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.

Branche
Biotechnologieforschung
Größe
2–10 Beschäftigte
Hauptsitz
Lausanne, Vaud
Art
Privatunternehmen
Gegründet
2021
Spezialgebiete
immunotherapy, metabolic und cancer

Orte

Updates

Ähnliche Seiten

Finanzierung

Leman Biotech Insgesamt 2 Finanzierungsrunden

Letzte Runde

Seed

7.000.000,00 $

Weitere Informationen auf Crunchbase